Nitroglycerine Versus Dexmedetomidine Infusion in Intraoperative Management of Uncontrolled Hypertension

CompletedOBSERVATIONAL
Enrollment

77

Participants

Timeline

Start Date

July 3, 2021

Primary Completion Date

November 20, 2022

Study Completion Date

December 10, 2022

Conditions
Hypertension
Interventions
DRUG

Nitroglycerin

data will be retrieved from intraoperative medical records for the period from May 2020 to May 2021 for patients meeting the eligibility criteria who developed uncontrolled elevation of their blood pressure and received nitroglycerine infusion

DRUG

Dexmedetomidine

All patients who develop uncontrolled elevation of their blood pressure and meeting the eligibility criteria from July 2021 to July 2022 will receive dexmedetomidine bolus of 1mic/kg over 20 minutes and then continuous infusion of 0.2-0.7 mic/kg/hour adjusted according to each patient hemodynamic response.

Trial Locations (1)

11796

National Cancer Institute, Cairo

All Listed Sponsors
lead

National Cancer Institute, Egypt

OTHER